An interventional study of Portal Message with Reminder Text Messages and Text Message with Reminder Text Messages in Lung Cancer, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 50 Years to 77 Years. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Screening
To evaluate the real-world effectiveness and implementation strategies for mPATH-Lung, investigators propose a pragmatic, randomized controlled trial across an academic Learning Health System. The trial will contrast several approaches to participant outreach and will specifically target engaging fully powered cohorts of racial/ethnic minorities and rural residents.
Primary Objective: Evaluate the real-world effectiveness of mPATH-Lung in increasing lung cancer screening rates across diverse populations.
Secondary Objectives
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 27,000 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Wake Forest University Health Sciences is the lead sponsor of 1,320 studies on the registry; 199 are open to participants now.
Of its 323 completed or terminated interventional studies of FDA-regulated products, 243 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Eligible patients will:
Exclusion Criteria:
The following patients will be excluded:
electronic health record Prior history of lung cancer electronic health record Chest CT within the last 12 months electronic health record Those meeting the HEDIS COL-E measure exclusion criteria based on significant comorbidities and/or frailty.
Patient portal message first followed by up to 3 reminder text messages.
Other: Portal Message with Reminder Text Messages
Text message only with up to 3 reminder text messages.
Other: Text Message with Reminder Text Messages
Portal message only with no reminder messages.
Other: Portal message only
Patients receive usual care.
Other: Usual Care
If the participant has an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial portal message, a final reminder text message a day before their scheduled appointment, and potentially an 'in progress' text message reminder if they start the mPATH-Lung program but do not complete it. If the participant does not have an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial portal message, the final reminder message 8 days after the initial message, and potentially an 'in progress' text message reminder.
If the participant has an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial message, a final reminder text message a day before their scheduled appointment, and potentially an 'in progress' text message reminder. If the participant does not have an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial message, the final reminder message 8 days after the initial message, and potentially an 'in progress' text message reminder.
Participant will only receive portal message with no reminder text messages.
Standard of care
Number of Participants to Complete Lung Screening CT - Primary Effectiveness
Completion of the lung screening CT by participants.
Time frame: 90 days
Number of Participants with Eligibility for Lung Screening
Reach of the mPATH-Lung platform, defined as the participants who determine their eligibility for lung screening within the mPATH-Lung program within 90 days of the first invitation. Investigators will determine reach overall, within subgroups, and within study arms.
Time frame: 90 days
Number of Requests for Lung Screening
Requests for lung screening within the mPATH-Lung program
Time frame: 90 days
Number of Orders for Lung Screening CT Scans
Orders for lung screening CT scans for participants in study arms
Time frame: Within 90 days of randomization
Amount of Revenue Generated
Revenue (costs) generated from lung cancer screening and follow-up care.
Time frame: 12 months following completion of screenings
Number of Participants that Represent Over-screening
Among patients with newly diagnosed lung cancer by lung screening, the participants that represent over-screening, defined as a patient being deemed too ill for potentially curative surgery on blinded chart review.
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences